Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Xian-Janssen And Nanjing Medical Resume Collaboration On Drug Distribution

This article was originally published in PharmAsia News

Executive Summary

Nanjing Medical and Xian-Janssen have ended their dispute over drug distribution (PharmAsia News, March 31, 2008), according to an insider, but the detailed compromise solution is not disclosed. The strained relations between the two firms have impacted Xian-Janssen's revenue, which dropped 20 to 30 percent in 2008. Based on the previous model, Nanjing Medical is now directly distributing Xian-Janssen's drugs in Fujian and Anhui provinces. However, Jiangsu is covered by Nanjing Huadong Medicine, which is Nanjing Medical's sister subsidiary under Nanjing Medical Industry (Group). The move shows Xian-Janssen's willingness to work indirectly with Nanjing Medical to avoid losing the latter's Jiangsu clients comprising 167 hospital pharmacies. (Click here for more - Chinese Language)

Latest Headlines
See All
UsernamePublicRestriction

Register

SC072441

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel